Literature DB >> 11471112

Subclinical Legionella infection in workers near the source of a large outbreak of Legionnaires disease.

H C Boshuizen1, S E Neppelenbroek, H van Vliet, J F Schellekens, J W den Boer, M F Peeters, M A Conyn-van Spaendonck.   

Abstract

A survey was conducted of exhibitors at a 1999 floral trade show, where a whirlpool spa on display caused a large outbreak of legionnaires disease (LD). In total, 742 exhibitors without LD returned a questionnaire on their whereabouts during the fair and their health afterward and supplied blood samples for the detection of IgM and IgG antibodies against Legionella pneumophila. The exhibitors had higher average antibody levels than did the general population. The closer to the whirlpool that the exhibitors worked, the higher their antibody levels. Both high-normal and high titer levels were found more frequently among workers with more exposure, suggesting that serosurveys among potentially exposed subjects are a valuable tool for outbreak investigation. Some differences in health complaints were observed between the more and less exposed groups, as estimated by the workplace location, but few differences were found between groups with different antibody levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11471112     DOI: 10.1086/322049

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires' disease in The Netherlands.

Authors:  Ed P F Yzerman; Jeroen W den Boer; Kamilla D Lettinga; Joop Schellekens; Jacob Dankert; Marcel Peeters
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

2.  Reference values for the SERION classic ELISA for detecting Legionella pneumophila antibodies.

Authors:  H C Boshuizen; J W Den Boer; H de Melker; J F P Schellekens; M F Peeters; J A van Vliet; M A E Conyn-van Spaendonck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-14       Impact factor: 3.267

3.  Evaluation of Vircell enzyme-linked immunosorbent assay and indirect immunofluorescence assay for detection of antibodies against Legionella pneumophila.

Authors:  Bram M W Diederen; Jan A J W Kluytmans; Marcel F Peeters
Journal:  Clin Vaccine Immunol       Date:  2006-03

4.  Vircell assays for detection of antibodies against Legionella pneumophila.

Authors:  Almudena Rojas; José Rojas; Joaquín Mendoza
Journal:  Clin Vaccine Immunol       Date:  2007-02

5.  Seroepidemiological study after a long-distance industrial outbreak of legionnaires' disease.

Authors:  E Wedege; T Bergdal; K Bolstad; D A Caugant; J Efskind; H E Heier; A Kanestrøm; B H Strand; I S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2009-02-18

Review 6.  Diagnosis of Legionella infection in Legionnaires' disease.

Authors:  J W Den Boer; E P F Yzerman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-12       Impact factor: 3.267

7.  High prevalence of antibodies to Legionella spp. in Danish blood donors. A study in areas with high and average incidence of Legionnaires' disease.

Authors:  M Rudbeck; K Mølbak; S Uldum
Journal:  Epidemiol Infect       Date:  2007-05-16       Impact factor: 2.451

Review 8.  Legionella and Legionnaires' disease: 25 years of investigation.

Authors:  Barry S Fields; Robert F Benson; Richard E Besser
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

9.  Legionella antibodies in a Danish hospital staff with known occupational exposure.

Authors:  M Rudbeck; S Viskum; K Mølbak; S A Uldum
Journal:  J Environ Public Health       Date:  2009-05-26

10.  Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapy.

Authors:  Kamilla D Lettinga; Annelies Verbon; Gerrit-Jan Weverling; Joop F P Schellekens; Jeroen W Den Boer; Ed P F Yzerman; Jacobus Prins; Wim G Boersma; Ruud J van Ketel; Jan M Prins; Peter Speelman
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.